Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1996-09-10
2000-05-16
Campell, Bruce R.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
435325, 435346, A61K 4800, C12N 1585
Patent
active
060633751
ABSTRACT:
An isolated cell having the characteristics of the cell line designated FO-1 #12 is provided. The cell FO-1 #12 is characterized as being .beta..sub.2 -microglobulin-deficient, neomycin-resistant and HAT-sensitive. A cell hybrid formed by the fusion of an FO-1 #12 cell or other cell described herein and a mammalian cell is provided. The patient-derived cell can be a tumor cell or other cell, such as a white blood cell. The patient-derived tumor cell can be a melanoma cell, a prostatic carcinoma cell, a colon carcinoma cell, a lung carcinoma cell, a breast carcinoma cell, a pancreatic carcinoma cell, or others. A method of treating AIDS in a patient, comprising administering to the patient a cell hybrid provided herein, wherein the patient-derived white blood cell is derived from the patient being treated, is provided. A method of treating solid tumor in a patient, comprising administering to the patient a cell hybrid as provided herein, wherein the patient-derived tumor cell is derived from the patient being treated, is provided.
REFERENCES:
Almond et al. "Protection Against SIV in Macaques-Implications for AIDS Vaccine Development" Abstract 209, Biotechnology Against AIDS Conference, Rockville, Maryland, Sep. 25-Oct. 1, 1994.
Kawakami et al., "Indentification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with in vivo Tumor Rejection" Proc. Natl. Acad. Sci. USA, 91:6458-6462, Jul. 1994.
Kawakami et al., "Cloning of the Gene Coding for a Shared Human Melanonma Antigen Recognized by Autologous T Cells" Proc. Natl. Acad. Sci. USA, 91:3515-3519, Apr. 1994.
D'Andrea et al. "Interleukin 10(Il-10) Inhibits Human Lymphocyte Interferon .gamma.-Production by Supressing Natural Killer Cell Stimulatory Factor/IL-12 Synthesis in Accessory Cells", J. Exp. Med., 178:1041-1048, Sep. 1993.
Brichard et al. "The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas" J. Exp. Med. 178:489-495, Aug. 1993.
Plautz et al. "Immunotherapy of Malignancy by in vivo Gene Transfer into Tumors" Proc. Natl. Acad. Sci. 90:4645-4659, May 1993.
Tripp et al. "Interleukin 12 and Tumor Necrosis Factor .alpha.are Costimulators of Interferon .gamma. Production by Natural Killer Cells in Severe Combined Immunodeficiency Mice. . . " Proc. Natl. Acad. Sci. USA 90:3725-3729, Apr. 1993.
Gastl et al. "Interleukin-10 Production by Human Carcinoma Cell Lines and its Relationship to Interleukin-6 Expression" Int. J. Cancer 55:96-101, 1993.
Towensend, Sarah E. and Allison, James P. "tumor Rejection After Direct Costimulation of CD8 T Cells by B7-Transfected Melanoma Cells" Science 259:368-370, Jan. 15, 1993.
Chen et al., "Costimulation of Antitumor Immunity by the B7 Countereceptor for the T Lumphocyte Molecules CD28 and CTLA-4" Cell 71:1093-1102, Dec. 24, 1992.
Boon, Thierry "Toward A Genetic Analysis of Tumor Rejection Antigens" Adv. Cancer Res., 58: 177-210, 1992.
Stott, E.J. "Anti-Cell Antibody in Macaques" Nature, 353:393, Oct. 3, 1991.
Oettgen, Herbert F. and Old, Lloyd J. "The History of Cancer Immunotherapy" in: Biologic Therapy of Cancer, DeVita, VT Jr, Hellman, S, and Rosenberg, SA, Eds., J.B. Lippincott Co., Philadelphia, 1991, pp. 87-119.
Toffaletti et al. "Augmentation of Syngeneic Tumor-Specific Immunity by Semiallogeneic Cell Hybrids" J. Immunol. 130(6):2982-2986, Jun. 1983.
Payelle et al. "Adoptive Transfer of Immunity Induced by Semi-Allogeneic Hybrid Cells, Against a Murine Fibrosarcoma" Int. J. Cancer 27:783-788, 1981.
Kim et al., "Tumor-Specific Immunity Induced by Somathic Hybrids. I. Lack of Relationship between Immunogenicity and Tumorigenicity of Selected Hybrids" J. Immunol. 123(2):733-738, Aug. 1979.
Kim, Byung S. "Tumor-Specific Immunity Induced by Somathic Hybrids. II. Elicitation of Enhanced Immunity Against the Parent Plasmacytoma" J. Immunol. 123(2):739-744, Aug. 1979.
Giovanella et al. "Human Neoplastic and Normal Cells in Tissue Culture. I. Cell Lines Derived from Malignant Melanomas and Normal Melanocytes" J. Natl. Cancer Inst. 56(6):1131-1142, Jun. 1976.
Parkman, Robertson "Tumor Hybrid Cells: An Immunotherapeutic Agent" J. Natl. Cancer Inst. 52(5):1541-1545, May 1974.
Jami, Jacques and Ritz, Evelyne "Expression of Tumor-Specific Antigens in Mouse Somatic Cell Hybrids" Cancer Res. 33:2524-2528, Oct. 1973.
Newton et al. "Melanoma Cell Hybrids as Cancer Vaccines" Proceedings of the Amer. Assoc. for Cancer Res. vol. 38, p. 398, Abstract 2671, Mar. 1997.
D'Urso et al. "Lack of HLA Class 1 antigen Expression by Cultured Melanoma Cells FO-1 Due to a Defect in B.sub.2 M Gene Expression", J. Clin. Invest. 87:284-292, Jan. 1991.
Hosoi et al. "A Human-Mouse Hybrid Cell Line Expressing both Human Leukocyte and Histocompatibility-2 Antigens" Japanese J. of Physiol. 49:297-304, 1990.
Gattoni-Celli Sebastiano
McClay Edward F.
Newton, III Danforth A.
Beckerleg Anne Marie S.
Campell Bruce R.
Medical University of South Carolina
LandOfFree
Semiallogeneic cell hybrids and related methods for treating can does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Semiallogeneic cell hybrids and related methods for treating can, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Semiallogeneic cell hybrids and related methods for treating can will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-256294